查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1784074

重組細胞培養補充劑的全球市場

Recombinant Cell Culture Supplements
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球重組細胞培養補充劑市場規模將達到 18 億美元

全球重組細胞培養補充劑市場規模預計在2024年為9.013億美元，預計到2030年將達到18億美元，在分析期內（2024-2030年）的複合年成長率為12.2%。重組白蛋白是本報告分析的細分市場之一，預計其複合年成長率為10.8%，到分析期結束時達到8.184億美元。重組胰島素細分市場在分析期間的複合年成長率預計為10.6%。

美國市場規模估計為 2.369 億美元，中國市場預計複合年成長率為 11.6%

美國重組細胞培養補充劑市場規模預計在2024年達到2.369億美元。作為世界第二大經濟體，中國市場規模預計在2030年達到2.817億美元，在2024年至2030年的分析期間內，複合年成長率為11.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為11.1%和10.7%。在歐洲，預計德國市場的複合年成長率約為9.1%。

全球重組細胞培養補充劑市場－主要趨勢和促進因素摘要

為什麼重組細胞培養補充劑會徹底改變生物製藥和研究產業？

重組細胞培養補充劑是現代生物製藥生產、再生醫學和幹細胞研究的基礎，為細胞培養系統提供必需的生長因子、荷爾蒙和營養物質。與傳統的血清類補充劑不同，重組細胞培養補充劑具有更高的一致性、更低的污染風險和更高的可擴展性，適合大規模生產。對單株抗體、疫苗和基因療法等生技藥品的需求不斷成長，推動了重組補充劑在生物加工中的應用。此外，組織工程和個人化醫療的進步進一步推動了對高品質、無動物成分的細胞培養補充劑的需求，以確保可重複性和法規遵循。隨著細胞療法和再生醫學的日益普及，重組細胞培養補充劑在推動創新研究和治療開發方面發揮關鍵作用。

科技進步如何增強重組細胞培養補充品？

重組蛋白表達、精製和配方方面的最新進展顯著提高了細胞培養補充劑的功效和性能。無血清和化學成分確定的培養基的開發消除了由於動物源性成分造成的變異性，確保了更可預測和可重複的細胞培養條件。蛋白質工程的創新也使得能夠生產高度特異性的重組生長因子、細胞激素和激素，從而最佳化細胞增殖、分化和生產力。此外，一次性生物製程和生物反應器技術的進步使得重組補充劑的大規模生產變得更容易、更具成本效益和擴充性。細胞培養最佳化中由人工智慧主導的預測模型和自動化正在進一步改進重組補充劑配方，加速研究和商業規模的生物製造。

哪些市場趨勢推動了重組細胞培養補充劑的需求？

生技藥品、基因療法和細胞檢測在藥物開發中的日益普及，推動了對重組細胞培養補充劑的需求。受一致、無污染生物製造製程監管要求的推動，轉向無動物成分、化學成分明確的培養基是關鍵趨勢。對再生醫學和幹細胞研究的日益關注，進一步推動了對支持受控細胞分化和增殖的重組生長因子和訊號分子的需求。此外，生物製藥契約製造組織 (CMO) 的擴張正在加速採用高性能重組補充劑，以提高產量並保持製程一致性。對 3D 細胞培養模型和器官晶片技術的日益關注也在塑造市場，需要支援複雜細胞微環境的先進細胞培養配方。

重組細胞培養補充劑市場的主要成長動力是什麼？

全球重組細胞培養補充劑市場的成長受到多種因素的推動，包括生物製藥產量的增加、細胞培養技術的進步以及監管部門對無血清和化學成分確定培養基的青睞。對單株抗體、細胞療法和個人化醫療的需求，大大推動了重組補充劑在生物加工中的應用。對降低細胞培養中變異性和污染風險的日益重視，進一步推動了市場擴張。此外，對幹細胞研究和組織工程的投資，為針對再生醫學應用的專用重組補充劑創造了新的機會。隨著蛋白質表現、製劑和生物製程最佳化的不斷創新，重組細胞培養補充劑市場有望實現顯著成長，從而支持生命科學、製藥和生物技術產業的發展。

部分

產品（重組白蛋白、重組胰島素、重組轉鐵蛋白、重組細胞激素、其他產品）、應用（生物製藥製造應用、再生醫學應用、其他應用）、最終用途（製藥和生物技術公司、細胞培養基製造商、契約製造組織/受託研究機構、合約開發和製造組織、學術研究機構）

受訪公司範例

  • Abcam plc
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Capricorn Scientific
  • Corning Incorporated
  • FUJIFILM Irvine Scientific Inc.
  • HiMedia Laboratories
  • InVitria
  • Kerry Group
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec
  • Novo Nordisk Pharmatech A/S
  • PeproTech（acquired by Thermo Fisher Scientific）
  • Repligen Corporation
  • Sartorius AG
  • Sino Biological Inc.
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Ventria Bioscience

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 比賽

簡介目錄
Product Code: MCP32763

Global Recombinant Cell Culture Supplements Market to Reach US$1.8 Billion by 2030

The global market for Recombinant Cell Culture Supplements estimated at US$901.3 Million in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 12.2% over the analysis period 2024-2030. Recombinant Albumin, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$818.4 Million by the end of the analysis period. Growth in the Recombinant Insulin segment is estimated at 10.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$236.9 Million While China is Forecast to Grow at 11.6% CAGR

The Recombinant Cell Culture Supplements market in the U.S. is estimated at US$236.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$281.7 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.1% and 10.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.

Global Recombinant Cell Culture Supplements Market - Key Trends & Drivers Summarized

Why Are Recombinant Cell Culture Supplements Revolutionizing Biopharmaceutical and Research Industries?

Recombinant cell culture supplements have become a cornerstone of modern biopharmaceutical production, regenerative medicine, and stem cell research, providing essential growth factors, hormones, and nutrients for cell culture systems. Unlike traditional serum-based supplements, recombinant cell culture supplements offer greater consistency, reduced risk of contamination, and improved scalability for large-scale manufacturing. The increasing demand for biologics, including monoclonal antibodies, vaccines, and gene therapies, has driven the adoption of recombinant supplements in bioprocessing. Additionally, advancements in tissue engineering and personalized medicine have further propelled the demand for high-quality, animal-free cell culture supplements that ensure reproducibility and regulatory compliance. As cell-based therapies and regenerative medicine gain traction, recombinant cell culture supplements are playing a crucial role in enabling innovative research and therapeutic development.

How Are Technological Advancements Enhancing Recombinant Cell Culture Supplements?

Recent advancements in recombinant protein expression, purification, and formulation have significantly improved the efficacy and performance of cell culture supplements. The development of serum-free and chemically defined media has eliminated the variability associated with animal-derived components, ensuring more predictable and reproducible cell culture conditions. Innovations in protein engineering have also enabled the production of highly specific recombinant growth factors, cytokines, and hormones that optimize cell proliferation, differentiation, and productivity. Additionally, advancements in single-use bioprocessing and bioreactor technologies have facilitated large-scale production of recombinant supplements, improving cost-effectiveness and scalability. AI-driven predictive modeling and automation in cell culture optimization are further refining the formulation of recombinant supplements, accelerating research and commercial-scale biomanufacturing.

What Market Trends Are Driving the Demand for Recombinant Cell Culture Supplements?

The increasing adoption of biologics, gene therapies, and cell-based assays in drug development has fueled demand for recombinant cell culture supplements. The shift toward animal-free and chemically defined culture media has been a key trend, driven by regulatory requirements for consistent, contamination-free biomanufacturing processes. The growing focus on regenerative medicine and stem cell research has further increased the need for recombinant growth factors and signaling molecules that support controlled cell differentiation and expansion. Additionally, the expansion of biopharmaceutical contract manufacturing organizations (CMOs) has accelerated the adoption of high-performance recombinant supplements to enhance production yields and maintain process consistency. The rising emphasis on 3D cell culture models and organ-on-a-chip technologies is also shaping the market, requiring advanced cell culture formulations to support complex cellular microenvironments.

What Are the Key Growth Drivers of the Recombinant Cell Culture Supplements Market?

The growth in the global recombinant cell culture supplements market is driven by several factors, including increasing biopharmaceutical production, advancements in cell culture technologies, and regulatory shifts favoring serum-free and chemically defined media. The demand for monoclonal antibodies, cell-based therapies, and personalized medicine has significantly boosted the adoption of recombinant supplements in bioprocessing. The growing emphasis on reducing variability and contamination risks in cell culture has further fueled market expansion. Additionally, investments in stem cell research and tissue engineering are creating new opportunities for specialized recombinant supplements tailored for regenerative medicine applications. With continued innovation in protein expression, formulation, and bioprocess optimization, the recombinant cell culture supplements market is poised for significant growth, supporting the advancement of life sciences, pharmaceuticals, and biotechnology industries.

SCOPE OF STUDY:

The report analyzes the Recombinant Cell Culture Supplements market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines, Other Products); Application (Biopharmaceutical Production Application, Regenerative Medicines Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Abcam plc
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Capricorn Scientific
  • Corning Incorporated
  • FUJIFILM Irvine Scientific Inc.
  • HiMedia Laboratories
  • InVitria
  • Kerry Group
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec
  • Novo Nordisk Pharmatech A/S
  • PeproTech (acquired by Thermo Fisher Scientific)
  • Repligen Corporation
  • Sartorius AG
  • Sino Biological Inc.
  • STEMCELL Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Ventria Bioscience

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Recombinant Cell Culture Supplements - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Shift Toward Serum-Free and Chemically Defined Media Drives Adoption of Recombinant Cell Culture Supplements
    • Rising Demand for Biologic Therapeutics Throws the Spotlight on High-Purity Supplementation
    • Growth in Monoclonal Antibody Production Strengthens Business Case for Optimized Cell Culture Performance
    • Increased Use of CHO Cells and Other Mammalian Systems Spurs Demand for Growth-Enhancing Supplements
    • Regulatory Pressure to Eliminate Animal-Origin Components Accelerates Market Shift to Recombinant Alternatives
    • Adoption of Scalable and GMP-Compliant Bioproduction Platforms Expands Addressable User Base
    • Technological Innovation in Recombinant Protein Expression Enhances Supplement Efficacy and Drives Demand
    • Use of Recombinant Transferrin, Insulin, and Albumin Improves Yield and Reduces Variability in Cell Cultures
    • Expansion of Cell-Based Vaccine Manufacturing Sustains Growth in Recombinant Supplement Usage
    • Integration with High-Throughput Bioreactors and Single-Use Systems Fuels Product Compatibility Needs
    • Increasing Bioprocessing Complexity Promotes Custom Supplement Formulations for Optimized Productivity
    • R&D Investment in Synthetic Biology Accelerates New Product Development in Cell Culture Ingredients
    • Demand for Cost-Efficient Media Components Supports Broad Adoption Across Academic and Industrial Labs
    • Use of Recombinant Supplements in Regenerative Medicine and Stem Cell Research Broadens Applications
    • Partnerships Between Biotech Firms and CDMOs Create Demand for Ready-to-Use, Flexible Supplement Solutions
    • Sustainability Goals and Ethical Sourcing Trends Propel Elimination of Animal-Derived Components
    • Rise in Cell and Gene Therapy Manufacturing Drives Need for High-Quality, Contaminant-Free Supplements
    • Focus on Reducing Lot-to-Lot Variability Supports Long-Term Contract Manufacturing Adoption
    • Stringent Quality and Traceability Norms in Biopharma Production Encourage Shift to Recombinant Inputs
    • Globalization of Biomanufacturing Infrastructure Expands Demand for Localized Supplement Supply Chains
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recombinant Cell Culture Supplements Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Recombinant Cell Culture Supplements by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Recombinant Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Recombinant Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Recombinant Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Recombinant Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Transferrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Recombinant Transferrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Recombinant Cytokines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Recombinant Cytokines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cell Culture Media Manufacturers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cell Culture Media Manufacturers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Contract Manufacturing Organizations & Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Contract Manufacturing Organizations & Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Contract Development & Manufacturing Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Contract Development & Manufacturing Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Academic Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Biopharmaceutical Production Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Biopharmaceutical Production Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Regenerative Medicines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Regenerative Medicines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 30: USA Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • CANADA
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • JAPAN
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • CHINA
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 52: China Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: China 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • EUROPE
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Recombinant Cell Culture Supplements by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 58: Europe Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Europe 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 60: Europe Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Europe 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • FRANCE
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 64: France Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: France 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 66: France Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: France 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • GERMANY
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 70: Germany Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Germany 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 72: Germany Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Germany 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 76: Italy Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Italy 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 78: Italy Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Italy 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • UNITED KINGDOM
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 82: UK Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: UK 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 84: UK Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: UK 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Rest of Europe 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 90: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of Europe 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Recombinant Cell Culture Supplements Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Asia-Pacific 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 96: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Asia-Pacific 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Product - Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Recombinant Cell Culture Supplements by Product - Percentage Breakdown of Value Sales for Recombinant Albumin, Recombinant Insulin, Recombinant Transferrin, Recombinant Cytokines and Other Products for the Years 2025 & 2030
    • TABLE 100: Rest of World Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by End-Use - Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Rest of World 6-Year Perspective for Recombinant Cell Culture Supplements by End-Use - Percentage Breakdown of Value Sales for Cell Culture Media Manufacturers End-Use, Contract Manufacturing Organizations & Contract Research Organizations End-Use, Contract Development & Manufacturing Organizations End-Use, Academic Research Institutes End-Use and Pharma & Biotech Companies End-Use for the Years 2025 & 2030
    • TABLE 102: Rest of World Recent Past, Current & Future Analysis for Recombinant Cell Culture Supplements by Application - Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Rest of World 6-Year Perspective for Recombinant Cell Culture Supplements by Application - Percentage Breakdown of Value Sales for Biopharmaceutical Production Application, Regenerative Medicines Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION